Changing the Patterns of Coxibs/NSAIDs Prescribing: Balancing CV and GI Risks CME
Program Co-Chairs: Byron Cryer, MD, Marc C. Hochberg, MD, MPH; Presenting Faculty: Charles H. Hennekens, MD, DrPH, Philip O. Katz, MD Disclosures
Release Date: February 15, 2006; Valid for credit through February 15, 2007
Contents of ThisCMEActivity
Medscape Editorial Note, February 2, 2006
Emerging information is creating debate about whether the benefits of COX-2 inhibitors ("coxibs") outweigh their cardiovascular risks. In addition, possible adverse effects of standard NSAIDs on the cardiovascular system are under scrutiny. Physicians as well as patients are uncertain about the optimal use of these agents. Medscape's NSAIDs and Cardiovascular Effects Alert Center provides links to articles and/or policy statements that update the evidence in this important therapeutic area. This Center is not intended to be a definitive source on the subject.
Changing the Patterns of Coxibs/NSAIDs Prescribing: Balancing CV and GI Risks Program Co-Chairs: Byron Cryer, MD, and Marc C. Hochberg, MD, MPH Presenting Faculty: Charles H. Hennekens, MD, DrPH, and Philip O. Katz, MD Introduction Cardiovascular Risk in the Rheumatology Patient: An Update Upper GI Tract Symptoms/Syndromes in the Rheumatology Patient: An Update The Nuances of Treating Upper GI Tract Symptoms in Patients With Rheumatic Diseases and/or Chronic Pain The Contemporary Use of NSAIDs and Coxibs in Patients With Arthritis and Musculoskeletal Disease Summary References
Legal Disclaimer
The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
This CME activity "Changing the Patterns of Coxibs/NSAIDs Prescribing: Balancing CV and GI Risks" is based on a CME-accredited satellite symposium held during the annual meeting of the American College of Rheumatology.
SCEPTER is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
SCEPTER designates this educational activity for a maximum of 1.5 Category 1 credits toward the American Medical Association (AMA) Physician's Recognition Award (PRA). Each physician should claim only those credits that he/she actually spent in the educational activity. Contact This Provider
